.jpg?format=webp&quality=80&width=3840)
The observational cohort report investigated the presentation and outcomes of patients with atopic dermatitis (AD) who developed musculoskeletal (MSK) symptoms after being treated with dupilumab, an IL-4 and IL-13 blocking monoclonal antibody. All patients responded well to dupilumab, and no specific predictors of the MSK syndrome were found. The severity of symptoms varied, with 16 patients experiencing mild symptoms, 6 having moderate symptoms, and 4 experiencing severe symptoms. Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or COX-2 inhibitors, reducing the dosage of dupilumab, and discontinuing therapy led to improvement. However, in cases with moderate or severe symptoms, the symptoms persisted for several months. This study highlights a new MSK syndrome associated with dupilumab and provides valuable insights into enthesitis pathogenesis and potential musculoskeletal side effects of cytokine-targeted therapies.
Like
Save
Share